Every Form 4 that Wave Life Sciences Ltd. (WVE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow WVE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WVE filings page.
Wave Life Sciences director Heidi L. Wagner exercised options for 7,000 ordinary shares at an exercise price of $5.97 per share on August 11, 2026, and sold the resulting 7,000 shares of common stock at $6.01 per share. The derivative position reported from this option grant was reduced to 0 following the transaction. The company notes these fully vested option exercises and related sale were effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2026.
Wave Life Sciences, Inc. director Adrian Rawcliffe reported selling 12,700 shares of common stock on August 12, 2026, in an open-market transaction at a reported price of $5.29 per share (weighted average). The sales were effected under a Rule 10b5-1 trading plan adopted on March 6, 2026, and left him with 0 shares of directly held common stock reported in this filing.
Wave Life Sciences, Inc. director Ken Takanashi reported selling 3,864 shares of common stock on August 11, 2026 at a weighted-average price of $6.01 per share, in transactions ranging from $6.01 to $6.03. The sale was made solely to cover taxes from restricted stock units vesting that day, pursuant to a previously adopted Rule 10b5-1 trading plan. After the sale, he directly held 20,079 shares and was reported as indirectly associated with 9,606,408 shares held by SNBL USA, Ltd. and Shin Nippon Biomedical Laboratories, Ltd., for which he disclaims beneficial ownership beyond any pecuniary interest.
Wave Life Sciences, Inc. director Tan Aik Na reported a small open-market sale of 432 shares of common stock on August 11, 2026 at $6.01 per share. According to the disclosure, the shares were sold solely to cover taxes from vesting restricted stock units on the same date, under a previously adopted Rule 10b5-1 Trading Plan. Following this transaction, the director directly holds 24,968 shares of Wave Life Sciences, Inc. common stock.
Wave Life Sciences Ltd. reported significant open-market buying by entities associated with RA Capital. RA Capital Healthcare Fund LP, advised by RA Capital Management, L.P., purchased a total of 8,772,496 ordinary shares in open-market transactions between March 26 and March 30, 2026 at prices around $6.06–$6.50 per share. Following these purchases, the Fund’s indirect holdings reached 26,975,505 ordinary shares, with an additional 28,815 shares linked to previously reported RSU awards held by Dr. Peter Kolchinsky for the benefit of the Fund. The Adviser, its general partner, the Fund, Dr. Kolchinsky and Mr. Rajeev Shah each disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
Wave Life Sciences Ltd. reported that entities associated with director Ken Takanashi converted 3,901,348 Series A preferred shares into the same number of ordinary shares on a one-for-one basis. This was a non-cash derivative conversion, not an open-market purchase or sale.
After the conversion, those entities collectively held 9,606,408 ordinary shares indirectly, while Takanashi also held 23,943 ordinary shares directly. Footnotes state the shares are held by SNBL USA, Ltd. and Shin Nippon Biomedical Laboratories, Ltd., and Takanashi disclaims beneficial ownership except to the extent of his pecuniary interest.
Wave Life Sciences Ltd. officer Francis Chris reported option exercises and share sales in Wave Life Sciences ordinary shares. On February 26, 2026, he exercised two share options for 17,900 and 15,294 shares at exercise prices of $3.87 and $4.75 per share, respectively, receiving the corresponding ordinary shares. He then sold 17,900 shares at a weighted-average price of $15.094 per share and 15,294 shares at $15.00 per share in open-market transactions. The filing notes these transactions were carried out under a pre-established Rule 10b5‑1 trading plan, and after the reported trades he held 61,867 ordinary shares directly.
Wave Life Sciences’ Chief Financial Officer Kyle Moran reported routine equity compensation and a related tax sale. On February 5, 2026, he received 45,625 restricted share units that vest in four equal annual installments from February 8, 2027 through February 8, 2030, and a share option for 273,750 ordinary shares at an exercise price of $12.75 per share, vesting 25% on February 8, 2027 and 6.25% quarterly thereafter until February 8, 2030. Following these grants, he held 137,973 ordinary shares and 273,750 options directly. On February 9, 2026, he sold 3,588 ordinary shares at $13.45 per share to cover taxes triggered by RSU vesting under an automatic sale provision, leaving 134,385 ordinary shares owned directly.
Wave Life Sciences Ltd. insider activity: President and CEO Paul Bolno received 165,000 restricted share units on February 5, 2026, bringing his direct holdings to 286,000 ordinary shares. These RSUs vest in four equal annual installments from February 8, 2027 through February 8, 2030.
On February 9, 2026, he sold 10,480 ordinary shares at $13.45 each solely to cover taxes from RSU vesting, leaving 275,520 shares owned directly. He also received a stock option for 1,000,000 ordinary shares at a $12.75 exercise price, vesting 25% on February 8, 2027 and 6.25% quarterly until February 8, 2030.
Wave Life Sciences (WVE) executive Chris Francis reported equity compensation grants and a small tax-related share sale. On February 5, 2026, he received 38,750 restricted share units that vest in four equal annual installments from February 8, 2027 through February 8, 2030, and a share option for 232,500 ordinary shares at an exercise price of $12.75 per share, vesting 25% on February 8, 2027 and 6.25% quarterly until February 8, 2030. On February 9, 2026, he sold 1,883 ordinary shares at $13.45 per share solely to cover taxes from RSU vesting, leaving 61,867 ordinary shares held directly.
Wave Life Sciences Ltd. executive Chandra Vargeese reported new equity awards and a small share sale. On February 5, 2026, Vargeese acquired 45,625 restricted share units, which vest in four annual 25% installments from February 8, 2027 through February 8, 2030. The same day, Vargeese received a stock option for 273,750 ordinary shares at an exercise price of $12.75, vesting 25% on February 8, 2027 and an additional 6.25% quarterly until February 8, 2030. On February 9, 2026, Vargeese sold 3,228 ordinary shares at $13.45 per share solely to cover taxes related to RSU vesting, as required under the RSU agreement. After these transactions, Vargeese directly held 408,246 ordinary shares and 273,750 options.
Wave Life Sciences Ltd. executive Chris Francis reported an option exercise and share sales in a Form 4. On January 2, 2026, Francis exercised 9,375 share options at an exercise price of $3.14 per share, receiving the same number of ordinary shares. On the same day, he sold 8,080 ordinary shares at a weighted-average price of $15.92 per share and 1,295 ordinary shares at a weighted-average price of $16.70 per share, in multiple transactions within disclosed price ranges. After these transactions, Francis directly owned 25,000 ordinary shares. The filing notes that these fully vested options and related sales were carried out under a Rule 10b5-1 trading plan adopted on August 5, 2025.
Wave Life Sciences Ltd. director reports option exercise and share sale. On December 8, 2025, director Adrian Rawcliffe exercised 42,000 share options for Wave Life Sciences ordinary shares at an exercise price of $5.97 per share. On the same day, he sold 42,000 ordinary shares at a sale price of $15.00 per share.
Following these transactions, Rawcliffe directly held 12,700 ordinary shares and no remaining share options. The filing states that the option exercise and related sales were carried out under a Rule 10b5-1 trading plan adopted on August 5, 2025, which is a pre-arranged plan intended to allow insiders to trade on a scheduled basis.
Wave Life Sciences Ltd. director reported stock transactions in company ordinary shares. On 12/08/2025, the insider exercised share options with an exercise price of $5.97 per share and sold 7,000 shares at $13 and another 7,000 shares at $14.
After these transactions, the reporting person directly owned 44,930 ordinary shares. The filing also shows share options to buy Wave Life Sciences ordinary shares at $5.97 that are fully vested and were transacted under a Rule 10b5-1 trading plan adopted on March 13, 2025.
Wave Life Sciences Ltd. director Gregory L. Verdine reported sales of company stock. On 12/08/2025, he sold 12,020 ordinary shares at a weighted-average price of $13.09 per share and 7,980 ordinary shares at a weighted-average price of $14.05 per share.
The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025. After these transactions, Verdine directly owned 275,217 ordinary shares of Wave Life Sciences. The price ranges for the sales were $12.75–$13.74 and $13.75–$14.70 per share, respectively.
Wave Life Sciences Ltd. executive reports option exercises and share sales. On December 8, 2025, a senior officer of Wave Life Sciences exercised multiple vested share options with exercise prices ranging from $2.83 to $10.48 per ordinary share and sold the resulting shares on the same day. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 5, 2025.
Following the reported option exercises and sales, the officer directly holds 25,000 ordinary shares. The filing notes that certain sale prices are reported on a weighted-average basis, including averages of $14.556 and $14.195 per share, and the officer has agreed to provide full pricing details upon request.
Wave Life Sciences Ltd. reported insider transactions by its Chief Financial Officer, Kyle Moran, in a Form 4 filing. On December 8–9, 2025, he exercised multiple share options and sold ordinary shares in the company.
The transactions included option exercises coded "M" and sales coded "S" in several tranches. Reported sales used weighted-average prices around $13.20, $15.00–$15.045, and $20.00–$20.22 per share, with the filing noting that detailed price breakdowns are available on request. These trades were carried out under a Rule 10b5-1 trading plan adopted on March 13, 2025.
After the reported transactions, Moran directly beneficially owned 90,365 ordinary shares of Wave Life Sciences and held several fully vested or scheduled-vesting share options with exercise prices ranging from $2.83 to $10.48 per share and expirations between 2030 and 2033.
Wave Life Sciences Ltd. director Christian Henry reported a series of option exercises and share sales in the company’s ordinary shares. On December 8, 2025, he exercised options to buy 42,000 shares at $5.97, 15,000 shares at $3.50, and 30,000 shares at $4.585 per share, all from fully vested options. He then sold 6,445 shares at $12.75, 42,000 shares at $12.75, 15,000 shares at a weighted-average price of $14.07 (with individual trades between $14.00 and $14.14), and 30,000 shares at a weighted-average price of $18.02 (with trades between $18.00 and $18.19). After these transactions, he directly owned 12,700 ordinary shares and retained options for 6,000 shares at $3.50 and 15,000 shares at $4.585. All trades were made under a Rule 10b5-1 trading plan adopted on August 6, 2025.
Wave Life Sciences Ltd. director Mark Corrigan reported open‑market sales of company ordinary shares under a pre‑arranged Rule 10b5‑1 trading plan. On December 8, 2025, he sold 9,600 ordinary shares at a weighted‑average price of $13.09 per share and later the same day sold an additional 6,515 ordinary shares at a weighted‑average price of $14.065 per share. After these transactions, he beneficially owned 35,330 ordinary shares following the first sale and 28,815 ordinary shares following the second, all held directly. The prices for each block reflect multiple individual trades within stated ranges, and full trade‑level details are available from the reporting person upon request.
Wave Life Sciences Ltd. (WVE) director Adrian Rawcliffe reported an open-market sale of company stock. On 11/13/2025, he sold 16,115 ordinary shares of Wave Life Sciences at a weighted-average price of $6.79 per share, in multiple transactions executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 5, 2025. After this transaction, the reporting person beneficially owned 12,700 ordinary shares, held directly.
The filing notes that the shares were sold in several trades within a price range of $6.64 to $7.00 per share, and the reporting person has undertaken to provide full details of the number of shares sold at each separate price upon request by the issuer, its security holders, or the SEC staff.
Wave Life Sciences (WVE): RA Capital Healthcare Fund, L.P. and affiliated reporting persons disclosed an open-market purchase of 1,000 ordinary shares on 11/13/2025 at a weighted average price of $6.6875. Following the transaction, they reported 18,203,009 shares beneficially owned indirectly. The purchase was made to extend the period for acquisitions under the fund’s Hart-Scott-Rodino filing. Previously reported 28,815 RSUs granted to Dr. Peter Kolchinsky are held for the benefit of the fund.